As expected, male hypogonadism is correlated with losses in bone quality, yet unexpectedly, the connection is not tightly dependent on testosterone levels. Multiple studies have shown that testosterone therapy can help improve bone mass and bone density in men with low testosterone and thereby can help to reverse the bone loss of osteoporosis. Testosterone can help lower the risk of bone fractures by improving bone density and help to replace the bone loss typical of patients with osteoporosis.
As men age, testosterone levels drop, putting them at greater risk of osteoporosis and osteoporosis-related fractures. TRT helps restore normal testosterone levels, which can improve bone mineral density and reduce the risk of fractures. Testosterone in men plays a similar role to oestrogen in women – lower levels of this hormone negatively affect bone health and may increase the risk of osteoporosis. Low testosterone levels can contribute to decreased bone mineral density and increase the risk of osteoporosis.
(4) Hypogonadotropic hypogonadism appears to correlate with lower bone quality than hypergonadotropic hypogonadism for unclear reasons. Testosterone signaling stimulates osteoblasts to form trabecular bone and helps osteocytes prevent trabecular bone loss. There have been some studies showing the benefit of Denosumab and Teriparatide on BMD in the male population in general 154–158. Orwoll et al. found no difference in lumbar BMD improvements between normal and low testosterone subgroups but did not comment on femoral BMD or fracture incidence. However, it would be difficult to justify extrapolating this data to hypogonadal males with established BMD deficits. In addition, subgroup analysis is needed to characterize the relationship of benefit with severity of testosterone deficiency, degree of baseline BMD loss, and the dose of testosterone replacement. Also, the variable rates for adverse effects of testosterone leave the issue of patient risk benefit still up for debate.
The MrOS study also had a North American study group looking at American men over the age of 65, but its results differed slightly from the Hong Kong and Swedish cohorts. A different study looked at the effect of global overexpression of human aromatase in mice and found that these animals had increased trabecular BMD, yet cortical bone effects were not analyzed in this study . There is however limited data on the selective effects of aromatase on bone structure regardless of gender, with the majority of data coming from the overexpression of aromatase in mouse animal models. Further studies need to be conducted to fully elucidate any role of the androgen receptor in osteoclast function. Finally, osteocytes also express the androgen receptor and demonstrate increased androgen receptor expression with osteocyte differentiation suggesting a role for testosterone in their function . Overall, there needs to be further research done on the exact role of testosterone in osteocyte signaling and function. Therefore, to best understand the specific effects of sex steroids on the bone, targeted knockouts in bone-specific cell lines such as osteoblasts, osteoclasts, and osteocytes should be used when trying to determine the role of sex steroids in bone function.
It seems reasonable to anticipate that low bioavailable levels of testosterone in aging men, similar to the decreased estrogen levels in menopause, would correlate to a loss in bone mineral density (BMD) and an increase in fracture risk. The clinical consequence of both primary and secondary hypogonadism, as well as testosterone decline in older males, on bone density and fracture risk in men will be summarized. While menopause and estrogen deficiency are well-known risk factors for osteoporosis in women, the effects of age-related testosterone decline in men on bone health are less well known.
While Testosterone Therapy can be beneficial for men with low testosterone levels and osteoporosis, it is important to note that it is not a standalone solution for bone health. By increasing testosterone levels, Testosterone Therapy helps promote bone formation and reduce the risk of fractures. While women experience a sudden decrease in estrogen during menopause, which affects their bone health, men's testosterone levels decline slowly over time. (5) Testosterone replacement therapy can effectively reverse hypogonadism-induced bone loss in men, yet bisphosphonates are considered first-line treatment for established osteoporosis in asymptomatic males. (3) Male hypogonadism results in declines of bone density and is correlated with increased fracture risk, yet estrogen plays the largest role in bone loss and fracture risk in older men.
If you take 1,000 mg/day of calcium from supplements, for example, it is better to take a smaller dose twice a day than to take it all at once. Some over-the-counter antacids, such as Tums and Rolaids, also contain calcium carbonate. The two main forms of calcium in dietary supplements are calcium carbonate and calcium citrate.
Epidemiological information on male osteoporosis arising from secondary causes, and male hypogonadism, specifically, is lacking, and therefore, the prevalence of male osteoporosis attributed to hypogonadism is unclear. A similar estimated prevalence of female osteoporosis reveals a significantly greater incidence for any age, including those under 70 years old (Table 1). The WHO has compiled data on the prevalence of male and female osteoporosis from different epidemiological studies around the world . Thus, regardless of whether one uses a female or male reference population, the traditional diagnostic category of BMD T-score SD ≤ −2.5 and between ≤1.0 and ≥2.5 is universally used to define osteoporosis and osteopenia in males aged ≥ 50, respectively. Furthermore, the importance of BMD measurements has decreased as emphasis has shifted away from BMD measurements for diagnosis, and more towards the clinically significant fracture risk assessment, of which BMD measurements are only one of many factors that are now considered.

Gender: Female

Social links